Literature DB >> 17211705

Which has superior acid-suppressive effect, 10 mg omeprazole once daily or 20 mg famotidine twice daily? Effects of single or repeated administration in Japanese Helicobacter pylori-negative CYP2C19 extensive metabolizers.

Tomohiko Shimatani1, Masaki Inoue, Tomoko Kuroiwa, Mutsuko Moriwaki, Jing Xu, Kazuro Ikawa, Norifumi Morikawa, Susumu Tazuma.   

Abstract

Low-dose omeprazole is superior to full-dose famotidine in maintenance therapy for gastroesophageal reflux disease, whereas "on-demand" famotidine is more effective for relief of episodes of heartburn. To explain this apparent discrepancy, intragastric pH was measured for 24-hr seven times in eight Japanese Helicobacter pylori-negative cytochrome P450 2C19 extensive metabolizers; on Days 1, 8, and 15 of repeated administration of 10 mg of omeprazole once daily and of 20 mg of famotidine twice daily and before medication. During repeated administration of omeprazole, mean intragastric pH and % time that intragastric pH > 4.0 were significantly higher and became greater. With famotidine, although these parameters were significantly higher, the degrees became smaller. Consequently, acid-suppressive effect was in the order; omeprazole < famotidine on Day 1, omeprazole approximately famotidine on Day 8, and omeprazole >famotidine on Day 15. This discrepancy possibly results from the "potentiation" of acid-suppressive effect of omeprazole and the "tolerance" phenomenon in respect to famotidine.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17211705     DOI: 10.1007/s10620-006-9490-9

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  55 in total

Review 1.  Improving on PPI-based therapy of GORD.

Authors:  G Sachs
Journal:  Eur J Gastroenterol Hepatol       Date:  2001-05       Impact factor: 2.566

2.  Intravenous pentagastrin can induce the illusion of 'tolerance' to a single dose of an H2-blocker in man.

Authors:  C U Nwokolo; A Sawyerr; J T Smith; R E Pounder
Journal:  Aliment Pharmacol Ther       Date:  1990       Impact factor: 8.171

3.  Prognostic factors influencing relapse of oesophagitis during maintenance therapy with antisecretory drugs: a meta-analysis of long-term omeprazole trials.

Authors:  R Carlsson; J P Galmiche; J Dent; L Lundell; L Frison
Journal:  Aliment Pharmacol Ther       Date:  1997-06       Impact factor: 8.171

4.  Effects of CYP2C19 genotypic differences in the metabolism of omeprazole and rabeprazole on intragastric pH.

Authors:  N Shirai; T Furuta; Y Moriyama; H Okochi; K Kobayashi; M Takashima; F Xiao; K Kosuge; K Nakagawa; H Hanai; K Chiba; K Ohashi; T Ishizaki
Journal:  Aliment Pharmacol Ther       Date:  2001-12       Impact factor: 8.171

5.  Self-Directed Treatment of Intermittent Heartburn: A Randomized, Multicenter, Double-Blind, Placebo-Controlled Evaluation of Antacid and Low Doses of an H(2)-Receptor Antagonist (Famotidine).

Authors:  Thomas J. Simon; Roger G. Berlin; Andrea H. Gardner; Laura A. Stauffer; A. Lawrence Gould; Albert J. Getson
Journal:  Am J Ther       Date:  1995-05       Impact factor: 2.688

6.  Post-prandial ranitidine is superior to post-prandial omeprazole in control of gastric acidity in healthy volunteers.

Authors:  R M Khoury; P O Katz; D O Castell
Journal:  Aliment Pharmacol Ther       Date:  1999-09       Impact factor: 8.171

7.  Omeprazole treatment of Korean patients: effects on gastric pH and gastrin release in relation to CYP2C19 geno- and phenotypes.

Authors:  Hyung-Keun Roh; Pum-Soo Kim; Don-Haeng Lee; Gunnel Tybring; Mohamed Sagar; Chang-Shin Park; Rein Seensalu; Leif Bertilsson
Journal:  Basic Clin Pharmacol Toxicol       Date:  2004-09       Impact factor: 4.080

8.  Lansoprazole versus ranitidine in the maintenance treatment of reflux oesophagitis.

Authors:  A L Gough; R G Long; B T Cooper; C S Fosters; A D Garrett; C H Langworthy
Journal:  Aliment Pharmacol Ther       Date:  1996-08       Impact factor: 8.171

9.  Identification of human liver cytochrome P450 isoforms mediating omeprazole metabolism.

Authors:  T Andersson; J O Miners; M E Veronese; W Tassaneeyakul; W Tassaneeyakul; U A Meyer; D J Birkett
Journal:  Br J Clin Pharmacol       Date:  1993-12       Impact factor: 4.335

10.  Effective maintenance treatment of reflux esophagitis with low-dose lansoprazole. A randomized, double-blind, placebo-controlled trial.

Authors:  M Robinson; F Lanza; D Avner; M Haber
Journal:  Ann Intern Med       Date:  1996-05-15       Impact factor: 25.391

View more
  1 in total

Review 1.  Histamine2-receptor antagonists: Rapid development of tachyphylaxis with repeat dosing.

Authors:  Johnson W McRorie; James A Kirby; Philip B Miner
Journal:  World J Gastrointest Pharmacol Ther       Date:  2014-05-06
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.